References
- Robinson SM, Adinoff B. The classification of substance use disorders: historical, contextual, and conceptual considerations. Behav Sci (Basel). 2016;6. doi:10.3390/bs6040028.
- Volkow ND, Koob G. Brain disease model of addiction: why is it so controversial? Lancet Psychiatry. 2015;2:677–79. doi:10.1016/S2215-0366(15)00236-9.
- Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047–53. doi:10.1016/S0140-6736(07)60464-4.
- Courtwright DT. A century of American narcotic policy. In: Gerstein DR, Harwood HJ, editors. Treating drug problems: volume 2: commissioned papers on historical, institutional, and economic contexts of drug treatment. Washington, DC: National Acadamies Press; 1992.
- Hall W. What are the policy lessons of national alcohol prohibition in the United States, 1920–1933? Addiction. 2010;105:1164–73. doi:10.1111/j.1360-0443.2010.02926.x.
- Blocker JS Jr. Did prohibition really work? Alcohol prohibition as a public health innovation. Am J Public Health. 2006;96:233–43. doi:10.2105/AJPH.2005.065409.
- Baum D. Smoke and mirrors: the war on drugs and the politics of failure. New York: Little, Brown and Company; 1997.
- Harrison Narcotics Act. Chap. 1, 38 Stat. 785. 1914. Available from: http://legisworks.org/sal/38/stats/STATUTE-38-Pg785.pdf [last accessed 21 Sept 2019].
- Drug Enforcement Agency (DEA). The early years. Available from: https://www.dea.gov/sites/default/files/2018-05/Early%20Years%20p%2012-29.pdf [last accessed 29 Sept 2019]
- Musto DF. The Marihuana Tax Act of 1937. Arch Gen Psychiatry. 1972;26:101–08. doi:10.1001/archpsyc.1972.01750200005002.
- Rothwell VL. Boggs Act. In: Kleiman MAR, Hawdon JE, editors. Encyclopedia of drug policy. Newbury Park: Sage Publishing; 2011.
- McWilliams J. The Protectors: Harry J. Anslinger and the Federal Bureau Of Narcotics, 1930–1962; Newark NJ: University of Delaware Press; 1990. p. 116
- Sharp EB. The dilemma of drug policy in the United States. New York: HarperCollins College Publishers; 1994.
- Drug Enforcement Agency (DEA). DEA History Book 1970 -1975. Available from: https://www.dea.gov/sites/default/files/2018-07/1970-1975%20p%2030-39.pdf [last accessed 22 Oct 2019].
- Anti-Drug Abuse Act of 1986. H.R.5484.1986. Access 1986.
- Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA. 1996;276:1580–88. doi:10.1001/jama.1996.03540190052029.
- Adinoff B, Reiman A. Implementing social justice in the transition from illicit to legal cannabis. Am J Drug Alcohol Abuse. 2019;45:673–688. doi:10.1080/00952990.2019.1674862.
- Narcotic Addict Act Marks Change in Policy. 1967. Available from: http://library.cqpress.com/cqalmanac/cqal66-1301488 [last accessed 29 Sept 2019].
- Nixon R. Statement on establishing the office for drug abuse law enforcement. 1972. Available from: https://www.presidency.ucsb.edu/node/254830 [last accessed 29 Sept 2019].
- Brown RT. Systematic review of the impact of adult drug-treatment courts. Transl Res. 2010;155:263–74. doi:10.1016/j.trsl.2010.03.001.
- Harm Reduction International. What is harm reduction? 2019. Available from: https://www.hri.global/what-is-harm-reduction [last accessed 21 Sept 2019].
- Wakhlu S. Buprenorphine: a review. J Opioid Manag. 2009;5:59–64.
- Hedrich D, Pirona A, Wiessing L. From margin to mainstream: the evolution of harm reduction responses to problem drug use in Europe. Drugs. 2008;15:503–17.
- Yoast R, Williams MA, Deitchman SD, Champion HC. Report of the council on scientific affairs: methadone maintenance and needle-exchange programs to reduce the medical and public health consequences of drug abuse. J Addict Dis. 2001;20:15–40. doi:10.1300/J069v20n02_03.
- Brodrick JE, Brodrick CK, Adinoff B. Legal regimes surrounding naloxone access: considerations for prescribers. Am J Drug Alcohol Abuse. 2016;42:117–28. doi:10.3109/00952990.2015.1109648.
- Collins SE, Lonczak HS, Clifasefi SL. Seattle’s law enforcement assisted diversion (LEAD): program effects on recidivism outcomes. Eval Program Plann. 2017;64:49–56. doi:10.1016/j.evalprogplan.2017.05.008.
- Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? Br J Criminol. 2010;50:999–1022. doi:10.1093/bjc/azq038.
- Laqueur H. Uses and abuses of drug decrminalization in Portugal. Law Social Inq. 2015;40:746–81. doi:10.1111/lsi.12104.
- Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191:55–62. doi:10.1192/bjp.bp.106.026112.
- Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, Strang J. van den Brink W. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health. 2007;84:552–62. doi:10.1007/s11524-007-9198-y.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug consumption rooms: an overview of provision and evidence (Perspectives on drugs). 2018. Available from: http://www.emcdda.europa.eu/publications/pods/drug-consumption-rooms_en [last accessed 22 Oct 2019].
- Crepault JF. Cannabis policy framework. 2014. Available from: https://www.camh.ca/-/media/files/pdfs—public-policy-submissions/camhcannabispolicyframework-pdf.pdf [last accessed 2 Oct 2019].
- Apfel F. Policy Brief 5. Cannabis - from prohibition to regulation. 2016. Available from: http://fileserver.idpc.net/library/ALICE-RAP-Policy-Paper-Cannabisfrom-Prohibition-to-Regulation.pdf [last accessed 3 Oct 2019].
- Caulkins JP, Kilborn ML. Cannabis legalization, regulation, & control: a review of key challenges for local, state, and provincial officials. Am J Drug Alcohol Abuse. 2019;45:689–697. doi:10.1080/00952990.2019.1611840.
- Shover CL, Humphreys K. Six policy lessons relevant to cannabis legalization. Am J Drug Alcohol Abuse. 2019;45:698–706. doi:10.1080/00952990.2019.1569669.
- Kilmer B. How will cannabis legalization affect health, safety, and social equity outcomes? It largely depends on the 14 Ps. Am J Drug Alcohol Abuse. 2019;45:664–672. doi:10.1080/00952990.2019.1611841.
- Caulkins JP, Kilmer B, MacCoun RJ, Pacula RL, Reuter P. Design considerations for legalizing cannabis: lessons inspired by analysis of California’s Proposition 19. Addiction. 2012;107:865–71. doi:10.1111/j.1360-0443.2011.03561.x.
- Smart R, Pacula R. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: findings from state policy evaluations. Am J Drug Alcohol Abuse. 2019;45:644–663. doi:10.1080/00952990.2019.1669626.
- Hasin DS, Shmulewitz D, Sarvet AL. Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings. Am J Drug Alcohol Abuse. 2019;45:623–643. doi:10.1080/00952990.2019.1569668.
- SarneY. Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC. Am J Drug Alcohol Abuse. 2019;551–562. doi:10.1080/00952990.2019.1578366.
- Burggren AC, Shirazi A, Ginder N, London ED. Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. Am J Drug Alcohol Abuse. 2019:563–579. doi:10.1080/00952990.2019.1634086.
- Tashkin DP, Roth MD. Pulmonary effects of inhaled cannabis smoke. Am J Drug Alcohol Abuse. 2019;45:596–609. doi:10.1080/00952990.2019.1627366.
- Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde M, Navon L, Hoots B, Salvatore PP, Elderbrook M, et al. Pulmonary illness related to E-cigarette use in Illinois and Wisconsin - preliminary report. N Engl J Med. 2019. doi:10.1056/NEJMoa1911614.
- Cooper ZD, Abrams DI. Controlled clinical studies examining both therapeutic and abuse-related outcomes of cannabis use. Am J Drug Alcohol Abuse. 2019.
- Ginsburg BC. Strengths and limitations of two cannabis-impaired driving detection methods: a review of the literature. Am J Drug Alcohol Abuse. 2019;45:610–622. doi:10.1080/00952990.2019.1655568.
- Crepault JF. Cannabis legalization in Canada: reflections on public health and the governance of legal psychoactive substances. Front Public Health. 2018;6:220. doi:10.3389/fpubh.2018.00220.